Protagonist Therapeutics, Inc (PTGX) stock
PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$124.67−0.16 (-0.13%)
Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –
Protagonist Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Protagonist Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was 20.7%. For fiscal 2025 it was -343.6%, against 58.2% the year before. The highest annual figure on record is 58.2% in fiscal 2024.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -343.6% | −401.8 |
| FY2024 | Dec 31, 2024 | 58.2% | +214.3 |
| FY2023 | Dec 31, 2023 | -156.1% | +338.1 |
| FY2022 | Dec 31, 2022 | -494.2% | −34.2 |
| FY2021 | Dec 31, 2021 | -460.0% | −234.7 |
| FY2020 | Dec 31, 2020 | -225.4% | +34632.2 |
| FY2019 | Dec 31, 2019 | -34857.6% | −34720.9 |
| FY2018 | Dec 31, 2018 | -136.7% | +52.2 |
| FY2017 | Dec 31, 2017 | -188.9% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 74.4% | +832.4 |
| Q1 FY2026 | Mar 31, 2026 | -6.5% | +61.7 |
| Q4 FY2025 | Dec 31, 2025 | -677.1% | −751.4 |
| Q3 FY2025 | Sep 30, 2025 | -985.2% | −98.5 |
| Q2 FY2025 | Jun 30, 2025 | -758.0% | +172.9 |
| Q1 FY2025 | Mar 31, 2025 | -68.2% | −149.1 |
| Q4 FY2024 | Dec 31, 2024 | 74.3% | +35.9 |
| Q3 FY2024 | Sep 30, 2024 | -886.7% | +3937.9 |
| Q2 FY2024 | Jun 30, 2024 | -931.0% | −848.9 |
| Q1 FY2024 | Mar 31, 2024 | 80.9% | +510.5 |
| Q4 FY2023 | Dec 31, 2023 | 38.4% | +368.2 |
| Q2 FY2022 | Jun 30, 2022 | -4824.6% | −3461.1 |
| Q1 FY2022 | Mar 31, 2022 | -82.1% | +306.1 |
| Q4 FY2021 | Dec 31, 2021 | -429.6% | −96.3 |
| Q3 FY2021 | Sep 30, 2021 | -329.8% | −270.6 |
| Q2 FY2021 | Jun 30, 2021 | -1363.4% | −727.2 |
| Q1 FY2021 | Mar 31, 2021 | -388.1% | +26.4 |
| Q4 FY2020 | Dec 31, 2020 | -333.3% | +605.7 |
| Q3 FY2020 | Sep 30, 2020 | -59.3% | +595.7 |
| Q4 FY2019 | Dec 31, 2019 | -636.2% | −482.7 |
| Q3 FY2019 | Sep 30, 2019 | -414.6% | −335.4 |
| Q1 FY2019 | Mar 31, 2019 | -939.0% | −862.6 |
| Q4 FY2018 | Dec 31, 2018 | -655.0% | −623.9 |
| Q3 FY2018 | Sep 30, 2018 | -153.5% | −96.8 |
| Q2 FY2018 | Jun 30, 2018 | -79.1% | – |
| Q1 FY2018 | Mar 31, 2018 | -76.3% | – |
| Q4 FY2017 | Dec 31, 2017 | -31.1% | – |
| Q3 FY2017 | Sep 30, 2017 | -56.7% | – |
See a number that looks wrong?